REG - EKF Diagnostics Hldg - Posting of Annual Report & Notice of AGM

EKF Diagnostics HoldingsAnnouncement

22/04/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV5356La&default-theme=true

RNS Number : 5356L  EKF Diagnostics Holdings PLC  22 April 2024

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Posting of Annual Report & Accounts
and
Notice of AGM

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that the Annual Report and Accounts for the year ended 31
December 2023 (the "Annual Report") and the Notice of the 2024 Annual General
Meeting  ("AGM") have now been published on the Company's website via
https://www.ekfdiagnostics.com/documents-reports.html
(https://www.ekfdiagnostics.com/documents-reports.html) .

 

The Annual Report, Notice of AGM and details for voting by proxy have all
been posted today to shareholders who have not consented to receive electronic
communications.

 

The AGM will be held at 11:00 am on 14 May 2024 at Harwood Capital LLP, 6
Stratton Street Mayfair, London W1J 8LD and will consider the resolutions set
out in the Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 11:00 am on Friday 10 May
2024. To register for dial-in details and to submit any questions please
contact Walbrook PR via email at ekf@walbrookpr.com
(mailto:ekf@walbrookpr.com)  or call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not automatically receive a hard copy form of proxy for the
AGM in the post. Instead, shareholders will be able to vote electronically
using the link available via https://www.signalshares.com
(https://www.signalshares.com) and selecting the "Proxy Voting" link, or
lodging a proxy appointment by using the CREST Proxy Voting Service.

 

Alternatively, shareholders may request a hard copy form of proxy directly by
calling the Registrars, Link Group, on Tel: 0371 664 0391. Calls are charged
at the standard geographic rate and will vary by provider. Calls outside the
United Kingdom will be charged at the applicable international rate. Lines are
open between 09:00 - 17:30, Monday to Friday excluding public holidays in
England and Wales.

 

 EKF Diagnostics Holdings plc                               www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Stephen Young, CFO         Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                      Tel: +44 (0)20 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR Limited            Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges.

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAITMMTMTITBLI